Payment overview · 2025
General Payments
$325.34
9 reported records · 5 companies
Healthcare provider profile · identity verified
Michael Tedder, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JONESBORO, AR · NPI 1962463091
Verified facts
What the public records show
CMS Open Payments records show Michael Tedder, M.D. received $325.34 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 51.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $166.93 | 51.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.98 | 27.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.80 | 11.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.25 | 5.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.38 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $325.34 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $152.63 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $89.98 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $62.47 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 723 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 374 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 73 |
| Azithromycin | Azithromycin | 293 | 198 |
| Potassium Chloride | Potassium Chloride | 281 | 52 |
| Omeprazole | Omeprazole | 268 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 257 | 57 |
| Losartan Potassium | Losartan Potassium | 253 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 243 | 48 |
| Metformin Hcl | Metformin Hcl | 219 | 58 |
| Simvastatin | Simvastatin | 210 | 44 |
| Meloxicam | Meloxicam | 205 | 69 |
| Tramadol Hcl | Tramadol Hcl | 195 | 52 |
| Diazepam | Diazepam | 192 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 189 | 40 |
| Gabapentin | Gabapentin | 175 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 41 |
| Furosemide | Furosemide | 162 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 39 |
| Lisinopril | Lisinopril | 148 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 49 |
| Allopurinol | Allopurinol | 135 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 41 |
| Sertraline Hcl | Sertraline Hcl | 131 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 29 |
| Jardiance | Empagliflozin | 124 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 15 |
| Eliquis | Apixaban | 115 | 16 |
| Atenolol | Atenolol | 108 | 22 |
| Estradiol | Estradiol | 100 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 21 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 94 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 93 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 25 |
| Carvedilol | Carvedilol | 91 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 80 | 14 |
| Lorazepam | Lorazepam | 79 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 12 |
| Clonazepam | Clonazepam | 69 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 68 | 15 |
| Cephalexin | Cephalexin | 67 | 53 |
| Ondansetron Odt | Ondansetron | 66 | 24 |
| Levofloxacin | Levofloxacin | 64 | 54 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 11 |
| Montelukast Sodium | Montelukast Sodium | 52 | 14 |
| Glimepiride | Glimepiride | 49 | 13 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 47 | 24 |
| Sotalol | Sotalol Hcl | 47 | suppressed |
| Fluconazole | Fluconazole | 45 | 25 |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 13 |
| Celecoxib | Celecoxib | 41 | 11 |
| Meclizine Hcl | Meclizine Hcl | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 11 |
| Finasteride | Finasteride | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 34 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Pentoxifylline | Pentoxifylline | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 23 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Premarin | Estrogens, Conjugated | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | 17 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | 11 |
| Testosterone | Testosterone | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $325.34 · 9 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, OTEZLA, Ozempic, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error